News

FDA vaccine chief leaving agency after less than 3 months
The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...
STAT3hOpinion
Vinay Prasad was not good for the FDA. But his ouster makes things worse
Vinay Prasad’s three-month tenure as one of the top officials at the Food and Drug Administration was bad for medicine. But ...
BioSpace4h
New CDER Head Tidmarsh Will Sub In At Biologics Group After Prasad’s Exit
George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...
Prasad’s FDA exit may accelerate cell and gene therapy approvals
Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...
Healio5h
Oncologist who served as FDA’s chief medical officer, top vaccine official departs agency
A controversial hematologist-oncologist who joined FDA this spring and quickly became its top regulator has left the ...
Devdiscourse5h
Vinay Prasad's Controversial Exit from the FDA
Vinay Prasad, appointed as FDA's top vaccine official, faced criticism and backlash during his short tenure. Controversies surrounded gene therapy safety and regulatory decisions affecting futures of ...
Senate confirms CDC director as top FDA official resigns under political pressure
In a 51–47 vote along party lines, the Senate confirmed Monarez as the director of the Centers for Disease Control and ...
FDA chief scientific officer Vinay Prasad resigns
Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...
The New York Sun6h
FDA’s Top Regulator Is Out Amid MAHA Backlash Over Blocking Access to a $3.2 Million Per Dose Therapy for Rare Disorder in Boys
Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...
BioSpace6h
Exit Stage Right: With Prasad Out, Analysts Hope for More Traditional Replacement
As analysts parsed news of Vinay Prasad’s ouster, worries over drug approval delays, cell and gene therapy impacts and more ...
STAT8h
Pharmalittle: We’re reading about Prasad leaving FDA, a pause on NIH spending, and much more
Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...
KFF Health News9h
Prasad Resigns From Top FDA Post Amid Fallout Over Sarepta Dispute
As director of the Center for Biologics Evaluation and Research, Dr. Vinay Prasad oversaw the regulation of vaccines and gene therapy drugs such as Sarepta Therapeutics' treatment for Duchenne ...